The tweet was deleted by the author.
But we saved everything 🙂.
Immuneering is participating in National Cancer Research Month, aligning with the American Association for Cancer Research (AACR), cancer centers, institutions, researchers, physicians, patients, survivors, and advocates to raise public awareness of cancer research.
The initiative emphasizes the importance and impact of ongoing cancer research and the collaborative effort required to advance medical breakthroughs. Immuneering reinforces its commitment to supporting both the scientific community and those affected by cancer.
Immuneering recently presented its Deep Cyclic Inhibitor atebimetinib for first line pancreatic cancer at the AACR 2026 meeting. CEO Ben Zeskind previously discussed the company’s early-stage research and approach to innovative cancer therapies on the BrewMarkets podcast. The company has highlighted ongoing efforts to improve treatment durability and outcomes for patients.